Combination of polypeptide AP25 and docetaxel in the treatment of breast cancer
10.3969/j.issn.1001-1978.2015.09.011
- VernacularTitle:多肽 AP25与多西他赛联合用药对人乳腺癌裸鼠移植瘤的抑制活性研究
- Author:
Jiayi WANG
;
Junjin HE
;
Jingchao HAO
;
Haoran CHENG
;
Hanmei XU
- Publication Type:Journal Article
- Keywords:
AP25;
docetaxel;
anti-tumor peptide;
breast cancer;
Guinness rules;
synergistic effect;
com-bination therapy
- From:
Chinese Pharmacological Bulletin
2015;(9):1233-1238
- CountryChina
- Language:Chinese
-
Abstract:
Aim To evaluate whether the combination of polypeptide AP25 and docetaxel is more efficient in treating experimental breast cancer,than either reagent used alone,and to offer suggestions for clinical use. Methods An experimental breast carcinoma model was set up to investigate the anti-tumor effects of AP25 and docetaxel combination.The Q value was caluculat-ed by Guinness rules and the anti-tumor effects of the combination of polypeptide AP25 and docetaxel were e-valuated.Results The treatment by the combination of polypeptide AP25 and docetaxel showed a better tumor inhibition rate.The combination of AP25 20 mg ·kg -1 and docetaxel 10 mg·kg -1 significantly inhibi-ted the tumor growth with 0.85
1.15,showing a synergistic effect.Conclusions The combination of AP25 and docetaxel can significantly in-hibit the tumor growth with a synergistic effect and de-crease the dose of chemotherapy.
